NEW YORK – Memory Treatment Centers on Friday said it has entered into a research collaboration with software company AiraMed to study the impact of beta-amyloid-targeting treatments on Alzheimer's disease patients.
Within the study, neurologists at Memory Treatment Centers, which has locations in Bonita Springs and Jacksonville, Florida, will use technologies from AiraMed to quantitatively assess brain volume in cognitively impaired patients receiving these treatments.
The US Food and Drug Administration earlier this summer approved Eli Lilly's anti-amyloid drug Kisunla (donanemab) as a treatment for Alzheimer's disease. That followed the approval of Eisai and Biogen's Leqembi (lecanemab), the only other anti-amyloid Alzheimer's treatment on the market, which gained full approval from the FDA last year after an initial accelerated approval.
Tübingen, Germany-headquartered AiraMed's technology uses artificial intelligence software to analyze and measure data from magnetic resonance imaging (MRI). Specifically, AiraMed's AiraScore software tracks changes in regional brain volume that may not be visible to the eye, according to the company.
"AiraMed will provide exact volumetric data — enabling us at MTC to get a better understanding for Alzheimer disease," Donald McCarren, a neurologist at Memory Treatment Centers, said in a statement. "Exact quantification of MR imaging data at the same time will allow us to monitor disease under therapy with precision."